Drug Profile


Alternative Names: A 64077; Abbott 64077; ABT 077; CRTX 073; CTI-02; Zileuton CR; Zyflo; ZYFLO CR; ZYFLO Filmtab

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories
  • Developer Chiesi USA; National Heart, Lung and Blood Institute; University of Minnesota
  • Class Antiasthmatics; Small molecules; Urea compounds
  • Mechanism of Action 5-lipoxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma
  • Discontinued Acne; Acute asthma; Allergic rhinitis; Atherosclerosis; Atopic dermatitis; Cancer; Chronic obstructive pulmonary disease; Nasal polyps; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 28 Apr 2014 Cornerstone Therapeutics is now called Chiesi USA
  • 04 Feb 2014 Cornerstone Therapeutics has been acquired by Chiesi Farmaceutici
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top